Equity
€21,781 from €166,251 in 2019
Equity fell by 87% in 6 years.
BLEUGIMED
Lifetime
11 annual accounts with figures on one time axispeak €226,237 (2025)
€226,237▲ 3.1%
peak €164,984 (2025)
€164,984▲ 3.4%
peak €166,251 (2019)
€21,781▼ 0.4%
€285,442▲ 14.9%
Board2 names since 2014
2 directors and 1 other
Documentsfilings and deeds
15-04-2026107 days before the deadline
2025financial year
Dividend €165,071Investments €26,592Cash from €10,327 to €16,761
Key points
from the 2025 annual accountsDebts
€285,442 93% of the balance sheet
Suppliers 0%Taxes and wages 12%Other 88%
Investments
€26,592 2.9 × depreciation
Green is investment, beige is depreciation. Land and buildings stand 48.1% higher than in 2024.
Filings
11 annual accounts since 2015
Seven of the last ten came late. The 2020 accounts came latest: 31 days after the end of the period.
Board
2 joined
New directors. Latest change 19-03-2026 · 2 in office.
Position in the sector
€21,781
Less equity than 85% of companies in human health. Sector median €448,200 · 504 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 1,325 companies had the same profile as BLEUGIMED has now. Each dot stands for 4 companies, two years later.
95.2%
were still trading
3.2%
stopped another way
1.4%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 1,325 companies, not a prediction for BLEUGIMED. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
2 directors reappointed
(director) and (director) · Permanent representative: · General meeting of 19-03-2026 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0563855159
Reappointments: (director) and (director)
General meeting of 08-11-2023 · Gazette deed
Reappointments: (director) and (director)
General meeting of 02-06-2020 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| BLEUGIMED Tournai | €307,223 | €226,237 | 7.1% | - |
| NASARR Brussels | €299,639 | €226,160 | 12.9% | - |
| Docteur A. CHACHATI Liège | €293,987 | €230,914 | 7.2% | - |
| SPINECO, Docteur Nicaise Namur | €311,930 | €238,190 | 29.3% | - |
| DOKTER FLEUR DE METSENAERE, GYNAECOLOGIE Maldegem | €314,170 | €219,629 | 86.3% | - |
| Plastische Chirurgie Dr. Marek Klinkenberg Eupen | €308,287 | €208,794 | 6.6% | - |
| DOCTEUR SYLVIE LEPAGE Chaudfontaine | €337,435 | €228,768 | 34.3% | - |
These companies have the same main activity as BLEUGIMED: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €294,000 and €337,000, founded between 2013 and 2015.
Official details
Source: KBO- Status
- Active since 09-10-2014Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Financial year end
- 31 December
- Peppol
- Reachable since 15-12-2025
Annual accounts 2025
- ≈ €420,000estimated
- €307,223▲ 13.7%
- Filing
- Filed on 15-04-2026, 107 days before the end of the filing period
Insights on BLEUGIMED
BLEUGIMED has existed since 2014. The gross margin grew from €138,482 in 2015 to €226,237 in 2025.
The gross margin has grown every year since 2020.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about BLEUGIMED
- What is the company number of BLEUGIMED?
- The company number of BLEUGIMED is 0563.855.159. The VAT number is the same number with BE in front: BE 0563.855.159.
- Where is BLEUGIMED based?
- The registered office is at Rue de Wattrelos (R-C) 33, 7520 Tournai.Company details
- What does BLEUGIMED do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of BLEUGIMED?
- BLEUGIMED is a private limited company (BV).
- When was BLEUGIMED founded?
- BLEUGIMED was founded on 09-10-2014.
- Is BLEUGIMED still active?
- Yes, BLEUGIMED is an active enterprise in the KBO register.
- What is the turnover of BLEUGIMED?
- The turnover in financial year 2025 is ≈ €420,000. This figure is estimated from the gross margin of €226,237 and 41 comparable companies (NACE 86220). It probably lies between €360,000 and €560,000.Financials
- Is BLEUGIMED profitable?
- In financial year 2025, BLEUGIMED made a profit of €164,984.
- Where can I find the annual accounts of BLEUGIMED?
- BLEUGIMED filed 11 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of BLEUGIMED due?
- BLEUGIMED must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.